These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, Andreeff M, Rassidakis GZ. Clin Cancer Res; 2007 Jun 01; 13(11):3380-7. PubMed ID: 17545546 [Abstract] [Full Text] [Related]
24. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Endo S, Yamato K, Hirai S, Moriwaki T, Fukuda K, Suzuki H, Abei M, Nakagawa I, Hyodo I. Cancer Sci; 2011 Mar 01; 102(3):605-13. PubMed ID: 21205074 [Abstract] [Full Text] [Related]
25. Inhibition of nutlin-resistant HDM2 mutants by stapled peptides. Wei SJ, Joseph T, Chee S, Li L, Yurlova L, Zolghadr K, Brown C, Lane D, Verma C, Ghadessy F. PLoS One; 2013 Mar 01; 8(11):e81068. PubMed ID: 24278380 [Abstract] [Full Text] [Related]
26. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F. Oncogene; 2008 Sep 11; 27(40):5303-14. PubMed ID: 18521084 [Abstract] [Full Text] [Related]
27. Histone deacetylase inhibitors enhance the anticancer activity of nutlin-3 and induce p53 hyperacetylation and downregulation of MDM2 and MDM4 gene expression. Palani CD, Beck JF, Sonnemann J. Invest New Drugs; 2012 Feb 11; 30(1):25-36. PubMed ID: 20680659 [Abstract] [Full Text] [Related]
28. MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H. Cancer Biol Ther; 2010 Jun 01; 9(11):936-44. PubMed ID: 20418664 [Abstract] [Full Text] [Related]
37. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin. Efeyan A, Ortega-Molina A, Velasco-Miguel S, Herranz D, Vassilev LT, Serrano M. Cancer Res; 2007 Aug 01; 67(15):7350-7. PubMed ID: 17671205 [Abstract] [Full Text] [Related]
38. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63. Gamble LD, Kees UR, Tweddle DA, Lunec J. Oncogene; 2012 Feb 09; 31(6):752-63. PubMed ID: 21725357 [Abstract] [Full Text] [Related]
39. On p53 revival using system oriented drug dosage design. Haseeb M, Azam S, Bhatti AI, Azam R, Ullah M, Fazal S. J Theor Biol; 2017 Feb 21; 415():53-57. PubMed ID: 27979498 [Abstract] [Full Text] [Related]